Influenza Virus Infection Clinical Trial
Official title:
A Phase 2, Multicenter, Randomized, Double-blind, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-1000 Compared With Placebo in Adult Patients With Acute Uncomplicated Influenza Virus Infection
To evaluate the antiviral effect of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection.
This study is a multicenter, randomized, double-blind, dose-ranging study to evaluate the efficacy and safety of different doses of TG-1000 compared with placebo in adult patients with acute uncomplicated influenza virus infection. Approximately 200 patients will be randomly assigned to 1 of 4 treatments groups in a ratio of 1:1:1:1 to receive study treatment orally: "40 mg TG-1000", "80 mg TG-1000", "40mg+40mg TG-1000" or "placebo". ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00981513 -
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
|
Phase 4 | |
| Completed |
NCT00792051 -
Direct and Indirect Benefits of Influenza Vaccine Versus Placebo in Healthy Children
|
N/A | |
| Not yet recruiting |
NCT03618407 -
Effect of Early Antiviral Therapy on Duration of Cough in Flu Patients
|
||
| Completed |
NCT04008823 -
Study of Influenza Virus Infection in Children Hospitalized in Spain in Two Consecutive Influenza Seasons
|
||
| Completed |
NCT02114255 -
Effects of BCG on Influenza Induced Immune Response
|
Phase 2/Phase 3 |